menu
    • menu

    Company profile for Hinova

    NEW Drugs in Dev: 5
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Hinova is an international and clinical-stage biopharmaceutical company engaged in the development of innovative deuterated and chimeric degraders for cancers and metabolic diseases. The company has 4 clinical-stage programs: HC-1119, a deuterated compound of enzalutamide, for the treatment of men with mCRPC; HP501, an URAT1 inhibitor, for hyperuricemia/gout treatment；HP558, a First-in-class CD44v6 inhibitor, for esophageal ...
    Hinova is an international and clinical-stage biopharmaceutical company engaged in the development of innovative deuterated and chimeric degraders for cancers and metabolic diseases. The company has 4 clinical-stage programs: HC-1119, a deuterated compound of enzalutamide, for the treatment of men with mCRPC; HP501, an URAT1 inhibitor, for hyperuricemia/gout treatment；HP558, a First-in-class CD44v6 inhibitor, for esophageal cancer treatment; and HP518, an oral AR degrader, with the potential to solve the drug resistance to prostate cancer due to AR variation

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HinovaChina Flag
    Country
    Country
    China
    Address
    Address
    No. 2 and No. 3, Floor 4, Building 1, Rongyao Building, Keyuan South Road 5, H...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.hinovapharma.com/en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hinova's HP518 Gets FDA Fast Track For AR+ Triple-Negative Breast Cancer
    Hinova's HP518 Gets FDA Fast Track For AR+ Triple-Negative Breast Cancer

    05 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hinova-pharmaceuticals-receives-fda-fast-track-designation-for-hp518-for-treatment-of-ar-triple-negative-breast-cancer-tnbc-302189976.html

    PR NEWSWIRE
    05 Jul 2024
    Share Share
    Hinova Receives FDA Proceed Authorization for its IND Application for HP518
    Hinova Receives FDA Proceed Authorization for its IND Application for HP518

    06 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hinova-receives-fda-proceed-authorization-for-its-ind-application-for-hp518-an-orally-bioavailable-chimeric-degrader-targeting-androgen-receptor-for-prostate-cancer-treatment-301739031.html

    PR NEWSWIRE
    06 Feb 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search